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ABSTRACT
Purpose We describe a novel class of antitumor amphiphilic
amines (RCn) based on a tricyclic amine hydrophilic head and
a hydrophobic linear alkyl tail of variable length.
Methods We tested the lead compound, RC16, for cytotoxicity
and mechanism of cell death in several cancer cell lines, anti
tumor efficacy inmouse tumormodels, and ability to encapsulate
chemotherapy drugs.
Results These compounds displayed strong cytotoxic activity
against cell lines derived from both pediatric and adult cancers.
The IC50 of the lead compound, RC16, for normal cells includ-
ing human keratinocytes, human fibroblasts and human umbil-
ical vein endothelial cells was tenfold higher than for tumor cells.
RC16 exhibited significant antitumor effects in vivo using several
human xenografts and a metastatic model of murine neuroblas-
toma by both intravenous and oral administration routes. The
amphiphilic character of RC16 triggered a spontaneous molec-
ular self-assembling in water with formation of micelles allowing
complexation of Doxorubicin, Etoposide and Paclitaxel. These
micelles significantly improved the in vitro antitumor activity of
these drugs as the enhancement of their aqueous solubility also
improved their biologic availability.
Conclusions RC16 and related amphiphilic amines may be
useful as a novel cancer treatment.
KEY WORDS antitumor activity . encapsulation of bioactive
molecules in micelles . formation of micelles in water . novel
amphiphilic amines . pharmacokinetics and biodistribution
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INTRODUCTION
Newer, targeted antitumor drugs currently in clinical use have
improved the outcome of many cancers by exploiting different
mechanisms of action to overcome resistance to chemotherapy
(1,2). However drug toxicity is often dose limiting, reducing the
chance to kill all tumor cells before they develop multidrug resis-
tance. Pediatric tumors in particular represent a serious challenge
to chemotherapy as they often grow fast and rapidly develop
resistance (3). Also, many types of adult tumors including breast,
colon and lung carcinoma frequently fail to respond to therapeu-
tic treatments due to drug resistance (4,5).
Among antitumor agents in development, the lipophilic
amines (6) appear particularly interesting. Their mechanism of
action is mainly located in mitochondria and lysosomes, unlike
inhibitors of DNA, RNA or RTKs that often induce resistance
through the expression of P-glycoprotein, multidrug-resistance
associated proteins or activation of alternative RTK pathways
(7). The alterations in mitochondria and lysosomes that occur in
cancer cells (8–18) make the anticancer effect of the lipophilic
amines quite specific. A major drawback to their clinical use,
however, is their high hydrophobicity, which restrains their bio-
availability and consequently their therapeutic efficacy.
We hypothesized that amphiphilic amines (RCn) whose mo-
lecular structure comprises a tricyclic amine hydrophilic head
and a hydrophobic linear alkyl tail of variable length would be
harmful to cancer cells and serve as drug-delivery vehicles. Our
primary objective was to determine the antitumor activity of
these novel agents alone in both pediatric and adult cell lines
and animal tumor models. Mice were used because of the avail-
ability of human tumor xenograft models. Our secondary objec-
tive was to determine the ability of these agents to be complexed
with other anticancer agents such as chemotherapy. Thus, RC16
was also evaluated as a nanocarrier for bioactive molecules as,
due to its amphiphilic character, it spontaneously self-assembles
in water into micelles able to complex hydrophobic drugs.
MATERIALS AND METHODS
Materials
DBC was purchased from Sigma-Aldrich. All the other re-
agents and solvents for the synthesis of the amphiphilic amines
were purchased from Fluka.
Cell Lines
Human cancer cell lines 143.98.2, A673, A549, CHLA20,
S462TY and Ramos have been previously described
(19–22). Normal primary HUVECs, Human Foreskin
Keratinocytes (differentiated) were also previously described
(22,23). Alveolar rhadomyosarcoma cell line Rh41 was ob-
tained from the Pediatric Preclinical Testing Program (Peter
Houghton, Nationwide Children’s Hospital) and maintained
in RPMI supplemented with 10% fetal bovine serum (FBS), l-
glutamine, and 100 IU/ml penicillin and 100 μg/ml strepto-
mycin. Murine neuroblastoma cell line Neuro2A, normal gin-
gival fibroblasts (24), and the human cancer cell lines SK-N-
AS (neuroblastoma), MDA-MB-231 (breast) andWIDr (colon
adenocarcinoma) were purchased from ATCC (Manassas,
VA). All cells purchased from the ATCC were maintained
according to supplier instructions.
Animal Studies
All animal studies were approved by the IACUC at
Cincinnati Children’s Hospital Medical Center (prior to the
lab’s relocation to Nationwide Children’s Hospital). Athymic
nude (nu/nu) and A/J female mice, 4–6 weeks old, weighing
20–25 g were purchased from Harlan Sprague Dawley
(Indianapolis, IN). Athymic nudemice were used to determine
RC16 maximum tolerated dose, pharmacokinetics, drug
biodistribution and efficacy in xenograft tumor models. A/J
mice were used to determine efficacy in an immunocompetent
tumor model. Animals were housed 4 mice/cage in the
Cincinnati Children’s Hospital Medical Center AAALAC
accredited facility. Mice were kept in specific pathogen free
rooms, which maintain constant temperature, humidity, and
light/dark cycle. Animals were observed daily by the animal
care staff including weekends. A full-time veterinarian was
available to ensure adequate veterinary care. Animals were
provided water and chow ad libitum. Cages and bedding were
changed once/week and all cages were maintained in racks
with independent sterile water and hepa-filtered airflow.
Determination of theMaximumToleratedDose inMice
To determine the MTD, a standard assay dose escalation
study was performed. Non-tumor bearing, female, athymic
nude mice were injected once with RC16 by the tail vein
starting with 0.5 mg/kg. The doses were escalated by
0.25 mg/kg until MTD was achieved. Following convention,
each dose was tested on a cohort of 5 mice in individual inde-
pendent experiments. MTD was defined as the highest dose
that could be given resulting in no drug-related moribund
state or death or body weight loss ≥ 20% in the first 7 days.
Other signs of toxicity such as unusual mouse behavior, lack of
movement and poor posture were also monitored. Mice were
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weighed and observed 3 times per week for any signs of tox-
icity. Mice that demonstrated signs of toxicity were humanely
euthanized by CO2 asphyxiation.
Pilot Pharmacokinetic Study in Mice
To establish a standard assay for RC16 detection and the half-
life of RC16 in murine blood, a basic pilot pharmacokinetic
study was performed using 1 animal per timepoint. Non-
tumor bearing, female, athymic nude mice were treated with
RC16 by i.v. or p.o.at doses of 1 mg/kg and 2 mg/kg, respec-
tively. At 2, 4, 6, 12, 24 and 48 h post RC16 administration, a
single mouse was anesthetized in an induction chamber with
5.0% isoflurane and an O2 flow rate of 0.8 L/min. Each
mouse was transferred to a nose cone supplying 5.0%
isoflurane with a O2 flow rate of 0.8 L/min. After confirming
sedation by testing hind footpads, each mouse was subjected
to exsanguination by cardiac puncture. Blood samples were
collected in BD Microtainers (BD, Franklin Lakes, NJ).
Plasma was separated by centrifugation at 2000×g for
10 min at 4°C and stored at −80°C until analysis. The
RC16 concentration in plasma was determined by liquid
LC-MS/MS.
Biodistribution Study
A pilot biodistribution study using one animal per timepoint
was performed to minimize the number of experimental ani-
mals. Female athymic nude mice were subcutaneously im-
planted with 5.0 × 106 CHLA-20 cells. When tumors became
palpable (approximately 5 mm in diameter), mice were treat-
ed with i.v. injections of RC16 labelled with Cell-Vue Maroon
(dye:RC16, 1:100 mol:mole) at a dose of 1 mg/kg. At 12, 24
and 36 h post RC16 injection, drug biodistribution was deter-
mined using the IVIS-200 (PerkinElmer, Waltham, MA) with
filter sets at 760/800 nm (excitation/emission). Themice were
then humanely euthanized by CO2 asphyxiation. Organs
were removed, weighed and used for quantitative optical im-
aging by the IVIS system.
In Vivo Efficacy Study
Xenograft Models
Female athymic nude mice were subcutaneously injected with
5 × 106 human cancer cells in 150 μLmix of PBS andmatrigel
(2:1). The mice were then randomized into groups of six ani-
mals for each tumor type. This number was chosen because we
sought a large effect size and to minimize numbers of mice.
When tumors reached a mean volume of 150 mm3, the ani-
mals were treated with RC16 or vehicle alone (PBS), given
slowly through the tail vein at the dose of 1 mg/kg, 3 times a
week for 3 weeks or orally gavaged at the dose of 2 mg/kg/day
for 3 weeks.
Immunocompetent Model
An efficacy study was performed on an immunocompetent mod-
el of neuroblastoma. In this experiment A/J mice were i.v.
injected with Neuro 2A (0.2 × 106 cells in 100 μL of PBS).
After 5 days, the mice were randomized (six animals per group)
and treated once with RC16 injected through the tail vein at
doses of 20 μg or 40 μg/mouse or vehicle (PBS). After treatment
animals were monitored for survival and endpoint criteria.
Endpoint Criteria
Endpoint criteria included tumor volume > 2000 mm3, body
weight loss ≥ 20%, unusual mouse behavior, lack of movement
and poor posture. Tumor size was measured using digital
calipers on alternate days and tumor volume was calculated
using the following formula: a x b2 π/6 where a is the longest
diameter and b is the shortest diameter. Mice were also
weighed and observed 3 times per week for signs of endpoint
condition. Mice that demonstrated signs of toxicity or reached
endpoint criteria were humanely euthanized by CO2
asphyxiation.
In Vitro Cell Proliferation Assays
Cells were plated in 96-well tissue culture plates at a density of
1 × 103 cells/well, allowed to attach 24 h, and then left un-
treated or treated with growth medium containing different
concentrations of the tested RCn compounds previously dis-
solved in PBS. After different time periods the cell vitality was
determined by MTT assay according to the manufacture’s
instruction (Promega). Results are reported as the micromolar
concentration of RCn reducing cell survival to 50% (IC50).
Western Blot Analysis
Cells with or without RCn treatment were washed with PBS
and lysed on ice for 30 min in lysis buffer containing protease
and phosphatase inhibitors. Protein concentrations were de-
termined with the Bio-Rad protein assay kit. 50 μg of total
protein was separated on 12% SDS-PAGE at 100 V for 1 h
and then transferred onto a nitrocellulose membrane using a
wet blotting apparatus (Bio-Rad Laboratories) at 20 V over-
night. Proteins were detected by enhanced chemilumines-
cence detection reagents (Amersham Biosciences). The anti-
bodies used for immunoblotting were: caspases 3, 8, 9, and
PARP were diluted 1:100 in blocking reagent (Cell Signaling
Technology). The exposure time was the same for all the
antibodies. Blots were stripped and reprobed with anti-β-
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tubulin diluted 1:10,000 in blocking reagent (Santacruz
Biotechnology) used as the loading control.
Caspase Activity Assays
Detection of caspase activity was evaluated by ApoFluor
Green Apoptosis Detection kits specific for: caspase-1 and
caspase-4; caspase-2, caspase-3 and caspase-7; caspase-6, cas-
pase-8, caspase-9, caspase-10, and caspase-13 (MP
Biochemicals), according to the manufacturer’s instructions.
Briefly, 5000 cells in 96-well microplates were detached with
EDTA and centrifuged at 400 × g for 5 min at room temper-
ature. Cell supernatants were removed, and the pellets resus-
pended in a buffer containing the appropriate caspase-specific
fluorescent probe. After 1 h incubation samples were washed
and analyzed by flow cytometry (FACScan, Becton
Dickinson) equipped with a 15-mW argon ion laser at
488 nm (16).
Flow Cytometric Analysis
SH-SY5Y, A673 and 143.98.2 cells were stained with
Annexin V-FITC/7AAD according to the manufacturer’s in-
structions (Biosciences). Briefly, adherent cells were seeded in
6 multi wells at a concentration of 4.5 × 105 cells/well and
after 24 h treated with 5 μM RC16 for15 h and 24 h. At the
end of the treatment the cells were detached, washed twice
with cold PBS and then suspended in annexin binding buffer
containing 5 μl of Annexin V-FITC and 5 μl of 7AAD. The
samples were gently vortexed and incubated 15 min at 25°C
in the dark. Finally, 400 ul binding buffer were added to each
tube and the samples were analyzed by BD LSR II
(Biosciences). The analysis was performed by FlowJo software
version 10.0.5.
Measurement of Intracellular ROS
Intracellular ROS were measured by OxiSelect™
Intracellular ROS Assay Kit (Cell Biolabs) following the man-
ufacturer’s instructions. Briefly, cells (1 × 105/mL) were
washed twice in PBS and incubated with 5 μM 2’,7’-
dichlorodihydrofluorescein diacetate (H2DCFDA) 1 h at
37°C. After PBS washes, the medium was changed with a
new one containing 5 μM RC16 for 15 h and 24 h. At the
end of the treatment samples were washed with PBS and a
mixture of medium and cell lysis buffer (1:1) was added for
5 min at 37°C. The fluorescence was read by a fluorimetric
plate reader (Spectra max M2, Molecular Device). Excitation




TEM studies were carried out on SH-SY5Y cells and HFs
incubated with 5 μM RC16 for 24 h. Cells were seeded on
cover glasses for 24 h and then the medium was replaced with
a fresh one containing 5 μMRC16 for 24 h. At the end of the
treatment the samples were washed with PBS and fixed with
2.5% glutaraldehyde in 0.1M phosphate buffer for 2 h at 4°C
and subsequently post-fixed with 1% OsO4 in 0.1 M phos-
phate buffer for 1 h at room temperature. After several washes
the samples were dehydrated in an acetone series (70, 90,
100%) and embedded in Epon resin (Fluka, Sigma-Aldrich).
Thin sections were collected on nickel grids, stained with ura-
nyl acetate and lead citrate, and observed under a TEM
(Philips CM10; FEI). Images were recorded using a
Megaview III digital camera (FEI). TEM was also used to
prove the formation of micelles in an aqueous environment
due to the amphiphilic nature of the RCn molecules. To this
purpose an aqueous solution of RC16 (20 μM) was stained
with 2% (w/v) phosphotungstic acid for 3 min on a copper
grid and subsequently it was visualized under TEM.
SEM Studies
SH-SY5Y cells were seeded on holders for 24 h and then the
medium was replaced with a fresh one containing 20 μMRC16
for 1 h. At the end of the treatment the samples were washed
with PBS and fixed for SEM in 2.5% glutaraldehyde, then
dehydrated in an ethanol series (70, 90, 100%) and critical
point dried. The dried specimens were sputter-coated with car-
bon and examined by FESEM (JSM 890, Jeol). The aqueous
solution of RC16 (20 μM) was desiccated at RT on the sample
holder, coated with carbon and examined by FESEM.
Interaction of RC16 with Sialic Acid
Neuraminidase was used to cleave the sialic acid residues from
the polysialilated glycoproteins and gangliosides of the tumor
cell surface and the anticancer activity of RC16 was subse-
quently tested in comparison with the cells not exposed to
Neuraminidase. Cells were seeded on 96 well plates at a den-
sity of 2 × 104 cells /plate and after 24 h were exposed to
50 IU/mL Neuraminidase Type VI from Clostridium
Perfrigens (Sigma) for 3 h. Cells were washed 3 times with
PBS and afterwards treated with RC16 . The effect on cell
number was evaluated after 24 h by MTT assay in compari-
son with cells not treated with Neuraminidase. The RC16 –
sialic acid interaction was also evaluated by adding sialic acid
to the culture medium in stoichiometric amount with respect
to RC16. In this experiment cells seeded on 96 well plates at a
density of 2 × 104 cells /plate and after 24 h were treated with
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a mixture of RC16 : sialic acid (3 μM : 3 μM). After 24 h the
effect on cell number was evaluated by MTT assay in com-
parison with cells treated with pure RC16 or pure sialic acid at
the same concentration (3 μM) of the mixture.
LC-MS/MS Analysis
Chromatographic separation was achieved using a Thermo
Scientific Accela UHPLC system with HTS PAL autosampler
and an Agilent ZORBAX Extend C18 column (50 × 2.1 mm
I.D, 3.5 μm particle size) with a C18 guard cartridge main-
tained at 35°C. A 6.0 min linear gradient program with wa-
ter/0.3% formic acid as mobile phase A and acetonitrile/0.3%
formic acid as mobile phase B at a constant flow rate of
400 μL/min was applied for elution: 0.0 min 25% B, 1.0 min
25% B, 3.0 min 95% B, 4.5 min 95% B, 4.6 min 25% B and
6.0 min 25% B. The autosampler sample draw was set to 4°C,
and a divert valve was used (0.0–2.0 min) to prevent early
eluting compounds from entering the MS. Selective reaction
monitoring with unit resolution was used for MS detection
under positive mode. Transition channels from the protonated
molecular ion to selected product ion were 377.33 > 153.15 for
RC16 and 251.20 > 153.15 for internal standard RC7, respec-
tively. Parameters optimized with a direct infusion of analyte
and IS using a syringe pump were as follows: spray voltage,
5000 V; sheath gas and auxiliary gas, 25 and 15 (arbitrary unit),
respectively; capillary temperature, 325°C; collision gas pres-
sure, 1.5mTorr and skimmer offset, 10 eV. Tube lens offset was
100 eV for both RC16 and RC7, respectively. Scan time was
0.03 s. Collision energies were 40 eV for RC16 and 33 eV for
RC7. Thermo Scientific LCQuan software was employed for
system control and data processing.
Ability of the RCn Micelles to Encapsulate Bioactive
Molecules
Aqueous solutions of RC16 (10 mM, 1 mL) were mixed with
ethanol solutions of Doxorubicin, Paclitaxel or Etoposide
(1 mM, 1 mL). After stirring 12 h at 25 C the mixtures were
dialyzed through 5000 Da MW cutoff dialysis membranes
against 100 ml water by changing the external medium every
8 h for 3 days. The RC16-drug complex collected after dialysis
was freeze-dried and the solid residue obtained was spectro-
photometrically analysed to estimate the percentage of drug in
the final product. The anticancer activity of each complexed
drug was evaluated in CHLA-20 as the difference between the
activity of the complex and the pure RC16 at the same con-
centration of the complex.
Statistical Analysis
For the in vitro assays, all data points represent mean± SD, n= 6
wells. All the experiments were repeated at least 3 times.
Representative data are shown. Statistical significance among
the mean values was analysed via an unpaired two-tailed
Student t-test assuming equal variance. For in vivo efficacy stud-
ies, n=6 animals. Six was determined to be the minimal num-
ber of animals necessary to be able to detect a large effect size.
For relative tumor volume (RTV), statistical significance among
the mean values was analysed via an unpaired two-tailed
Student t-test assuming equal variance. Survival statistical sig-
nificance was determined using the Log-Rank (Mantel-Cox)
test on Graph Pad Prism (La Jolla, CA). The significance (p-
value) was set at the nominal level of 0.05 or less.
RESULTS
Synthesis of the Amphiphilic Amines
The amphiphilic amines were synthesized following the
scheme descr ibed in F ig . 1 . A mix ture of 1 ,8 -
diazabicyclo[5.4.0]undec-7-ene (DBU) and the appropriate
alkene (in a 1:3 Molar ratio) in N-methylpyrrolidone was
stirred at room temperature 4 h in the presence of
2-[2-(ethenyloxy)ethoxy]ethan-1-ol 0.2 M as a catalyst.
Addition of diethylether induced the precipitation of a solid
residue that was purified by flash chromatography using a
mixture of methanol/water (9:1) as eluent. The final products
were characterized by 1H NMR, 13C NMR, mass spectra,
and elemental analysis (Supplemental Material).
In Vitro Cell Killing
Time-dependent and dose-dependent cell killing was observed in
the presence of all the RCn compounds of the series (Table I).
Differences in activity were obtained among the different RCn
with RC16 resulting the most active against all the pediatric tu-
mor cell lines analyzed (Table I). Under light microscopy, cells
showed characteristic morphologic changes consistent with cell
death (Fig. 2). Due to its improved antitumor activity, RC16 was
further evaluated on a set of adult tumor cell lines (A549, MDA-
MB-231, WiDr) selected for being particularly resistant to the
current antitumor treatments. RC16 was very active with IC50
values in the low micromolar range (1–10 μM, Table II). The
evaluation RC16 on the normal cell lines demonstrated, on the
contrary, very low potency with IC50 values for human
keratinocytes, human fibroblasts and HUVEC more than ten-
fold higher than those for tumor cells (Table II).
Induction of Apoptosis
We tested the ability of RC16 for the induction of apoptosis. As
shown in Fig. 3a control and treated cells were gated into LR
(Lower Right), UR (Upper Right), LL (Lower Left) and UL
(Upper Left) quadrants. Cells in LR and UR were considered
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as early apoptotic (annexin+/7AAD-) and late apoptotic
(annexin+/7AAD+) respectively. Cells in LL and UL were
considered live (annexin-/7AAD-) and necrotic (annexin-/
7AAD+), respectively. Flow cytometric analysis showed that
the percentage of cells in apoptosis increased over time with
differences among the different cell lines. At 15 h the extent of
apoptosis expressed as the sum of the percentages in LR and
UR quadrants was higher in A673 and lower in 143.98.2.
After 24 h all the cells showed approximately 100% apoptosis.
These data indicate the apoptotic mode of cell death in all the
cell lines analyzed and a different rapidity of cell death de-
pending on the cell type. Differences between control and
treated cells are statistically significant at any time of treatment
(p= 0.016 vs control). To further confirm the apoptotic nature
of cell death induced by RC16 in tumor cells, we also evaluat-
ed whether caspases were involved in the death process. We
performed both western blot analysis and fluorimetric assays
on SH-SY5Y cells in the presence of RC16 . The western blot
analysis indicated activation of caspases 3, 8 and 9 after
exposure to RC16 (Fig. 3b), suggesting the induction of both
extrinsic and intrinsic apoptosis. In the fluorimetric assays we
used different commercially available kits for single caspases
(i.e., caspase-1, caspase-2, caspase-3, caspase-6, caspase-8, cas-
pase-9, caspase-10, and caspase-13) and measured the in-
crease in fluorescence after 1, 2, 4, 6, 12, and 24 h in SH-
SY5Y cells exposed to RC16. As shown in Fig. 3c all the above
caspases were activated already at 4 h and became more ac-
tive thereafter in treated tumor cells with respect to controls.
Electron Microscopy Analysis of RC16 Treated Cells
and the Encapsulation Ability of RC16 Micelles Towards
Bioactive Molecules
SH-SY5Y cells treated with RC16 for 24 h showed a polygonal
morphology in which nucleus and nucleolus were well pre-
served while cytoplasm was characterized by several vacuoles
of different diameters (Fig. 4a). At higher magnification dam-
aged mitochondria with no clear cristae were easily detected
Fig. 1 Schema for the synthesis of RCn compounds. (i) N-methylpyrrolidone (NMP), 2-[2-(ethenyloxy)ethoxy]ethan-1-ol CH2=CH-(O-CH2CH2)2-OH as a
catalyst, 4 h, room temperature.
Table I Cell killing activity of RCn compounds on pediatric tumor cell lines (IC50 (μM)) at 24 and 48 h*
Cell Line Tissue Type RC7 RC10 RC12 RC14 RC16 RC18 RC20
24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h
A673 Ewing’s Sarcoma 5.73 4.11 2.60 2.02 1.82 1.65 1.27 1.13 0.80 0.65 1.03 0.98 1.22 1.35
143.98.2 Osteosarcoma 4.51 3.78 2.55 1.68 1.98 1.24 1.31 0.78 0.50 0.32 0.92 0.65 1.09 0.83
SK-N-AS Neuroblastoma 5.21 3.43 2.14 1.56 1.87 0.71 1.20 0.63 0.88 0.67 1.23 0.75 1.60 0.90
S462TY Malignant Peripheral
Nerve Sheath Tumor
5.62 3.90 2.39 1.78 2.00 1.09 1.81 0.95 1.11 0.76 1.67 0.88 1.83 1.16
Ramos Lymphoma 4.55 3.12 2.10 1.03 1.18 0.74 0.96 0.22 0.10 0.04 0.83 0.17 0.97 0.20
Rh41 Rhabdomyosarcoma 5.78 4.01 2.85 2.03 1.75 1.16 1.36 0.97 0.25 0.15 1.01 0.82 1.68 1.12
* Data are representative of three independent experiments
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as well as late autophagy vacuoles (lysosome like vacuoles) with
materials at different stages of degradation. Damaged rough
endoplasmic reticulum and multilamellar bodies connected
with phospholipid degradation were also observed (Fig. 4a).
Human fibroblasts treated with RC16 at the same concentra-
tion and duration showed a fibroblastic morphology and a
nucleus well preserved (Fig. 4b). Several small vacuoles were
detected in the cytoplasm. Normal mitochondria were ob-
served, while some autophagy vacuoles connected with an
early process were detected (Fig. 4b). The formation of mi-
celles, triggered by the spontaneous self-assembling of the am-
phiphilic RC16 molecules in water, was confirmed by Electron
Microscopy. SEM and TEM images of RC16 in the presence
of SH-SY5Y cells displayed micelles of spherical shape and
regular surface (Fig. 4c, d). Measure of their mean diameter,
performed by TEM, provided values in the nanometric range
(20–30 nm). The RC16 micelles were able to encapsulate the
antitumor drugs studied. The encapsulation efficiency, calcu-
lated as the weight percentage of drug in the final complex,
followed the order: Doxorubicin (2.3 ± 0.78%) > Paclitaxel
(1.8 ± 0.73%) > Etoposide 1.0 ± 0.59%). The anticancer acti-
vity of the complexed drugs resulted in each case higher than
the free drugs at the same concentrations of the complex. The
highest improvement in anticancer activity with respect to the
free drug was observed in the presence of Doxorubicin
(Table III).
Evaluation of Intracellular ROS and the Interaction
of RC16 With Sialic Acid
The evaluation of intracellular ROS confirmed the damage to
mitochondria observed by electron microscopy. After treat-
ment with RC16, intracellular ROS increased in all the tumor
cell lines analysed. The highest increase was observed in A673
where the ROS levels became more than twice the control
values after 15 h of cell exposure to RC16 (Fig. 5a). In SH-
SY5Y and 143.98.2 the ROS increase occurred after longer
time periods (24 h) of cell exposure to RC16 with lower level
increase relative to the controls.
The pre-treatment of cells with Neuraminidase, decreasing
the presence of sialic acid on the glycoproteins and ganglio-
sides of the cell surface, decreased the anticancer activity of
RC16 (Fig. 5b) supporting the hypothesis of an interaction of
RC16 with the sialic acid residue of the cell membrane as a
contribution to its whole mechanism of action. As confirma-
tion, the addition of sialic acid to the culture medium,
interacting with RC16 and therefore decreasing its availability
towards the sialic acid residues present on the glycoproteins
and gangliosides of the tumor cell surface, decreased the RC16
anticancer activity (Fig. 5c).
Maximum Tolerated Dose in Mice
Prior to initiation of the experiment, animals were naïve to
drug and weighed an average of 0.023 kg. The maximum
tolerated dose of RC16 by intravenous route was 4 mg/kg.
At this dose 5/5 (100%) survival was obtained with no body
weight loss with respect to the controls. Moreover, no signs of
toxicity such as altered mouse behavior, movement or diar-
rhea were observed. By increasing the dose above 4 mg/kg a
progressive decrease in survival was observed with a 0/5 (0%)
survival at 5.5 mg/kg.
Fig. 2 Light microscopy analysis of 143.98.2 tumor cells treated for 24 h with 5uM RC16. The cells appeared reduced in the number, rounded in shape and
almost detached from the plastic surface of the flask. All these morphological features are consistent with cell death (magnification 10×). Similar findings were
observed in all other cancer cell lines treated with RC16.
Table II Cell killing activity of R-C16 on adult tumor and normal cell lines
(IC50 (μM)) at 24 and 48 h)*




Normal Cell Lines 24 h 48 h
Human Foreskin Keratinocytes (differentiated) 15.20 13.46
Human Gingival Fibroblasts 11.80 10.50
HUVEC 10.63 9.65
*Data are representative of three independent experiments
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Pharmacokinetics and Biodistribution of RC16
The pilot pharmacokinetic data were obtained after RC16 ad-
ministration at 1 mg/kg in mice by i.v. or 2 mg/kg by oral route.
Each data point is from a single mouse. At 2 h post i.v. admin-
istration, the plasma concentration was 153 ng/mL with a con-
tinued decline to 11.4 ng/mL by 24 h and ameasured half-life of
5.4 h (Fig. 6a). After oral administration the maximum observed
plasma concentration of RC16 was 12.5 ng/mL at 4 h. The
concentration continued to decline and was measured at
0.5 ng/mL and 4.6 ng/mL in the plasma samples collected from
the mice euthanized at 24 and 48 h, respectively (Fig. 6a). Non-
compartmental analysis of these pilot data indicated an apparent
half-life of 5.2 h, similar to that from intravenous dosing. The
pharmacokinetic parameters of RC16 following intravenous and
oral administration in nude mice are summarized in Fig. 6b.
Bioluminescence images showed an extensive distribution
of fluorescence in the whole body at 12 h and a gradual
decrease of distribution at 24 and 36 h with a persistence of
fluorescence in the liver and the gastrointestinal system
(Fig. 6c). For a quantitative evaluation of biodistribution the
organs were removed from the euthanized mice at 12, 24 and
48 h after i.v. injection of the labelled RC16 and were imaged
immediately after dissection. All images were acquired for 5 s
and processed using the Xenogen Living Image software (25).
The fluorescence intensity (photons/second, (p/s)) was calcu-
lated per unit weight of each organ (26), and the results are
shown in Fig. 6d. At each time point stomach, intestine and
liver showed the highest fluorescence intensity. All the organs
showed a decrease in RC16 content over time except the tu-
mors whose RC16 level remained constant over time.
In Vivo Efficacy Studies
Prior to initiation of the experiment, animals were naïve to
drug and weighed an average of 0.023 kg. Administration of
Fig. 3 Induction of Apoptosis by RC16. (a) Annexin V-FITC/7ADD stained fluorescence-activated cell sorter (FACS) in SH-SY5Y, A673 cells and 143.98.2 cells.
All the samples were treated with 5 μM RC16 for 15 and 24 h. (b) Western blot analysis of SH-SY5Y cells treated with 5 μM RC16 for 2, 8, 12, 24 and 36 h for
caspase 3, 8 and 9. H3h, H9h: Hela treated with 5 μM staurosporine for 3 and 9 h (positive control of apoptosis); S9h: SH-SY5Y treated with 5 μM staurosporine
for 9 h (positive control of apoptosis). (c) Fluorimetric assay of caspases 1, 2, 3, 6, 8, 9, 10, 13 activation in SH-SY5Y cells treated with RC16 5 μM for 1, 2, 4, 6, 12
and 24 h (p<0.05).
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RC16 to six mice bearing human tumor xenografts in each
treatment group demonstrated a strong antitumor activity by
both intravenous and oral administration (Fig. 7a). No weight
loss or signs of toxicity were observed in any case during the
treatment period indicating good tolerability of RC16 both by
intravenous administration and gavage. In the metastatic
model of neuroblastoma disease the mice showed a significant
increase in the mean survival time with respect to the controls
(Fig. 7b) indicating a strong activity of RC16 after a single
intravenous administration. At the end of the experiment
(90 days) 3 of the 12 RC16 treated mice were healthy and alive
and showed no evidence of macroscopic disease at necropsy.
DISCUSSION
We created and tested a novel class of amphiphilic amines
(RCn) based on a tricyclic hydrophilic head and a hydropho-
bic alkyl linear tail of variable length for their antitumor ac-
tivity and their ability to complex bioactive molecules. We
observed anticancer activity of the RCn amines in all of the
cancer cell lines analysed, including both pediatric and adult
tumors, greater than seen in the normal cells.
RC16, characterized by an intermediate alkyl tail length, ex-
hibited the strongest anticancer activity in the series and was
chosen as a lead compound for further study. RC16 exhibited
significant antitumor activity in several cancer models by both
intravenous and oral routes. Mechanistic studies suggest RC16
binds to sialic acid residues on the cell membrane and induces
cell death via mitochondrial and lysosomal damage. Both acti-
vities are likely to account for the differential effects on tumor
compared with normal cells. The interaction with sialic acid is an
interesting target in cancer research as it enables selectivity for
tumor cells due to high levels of the polysialilated glycoproteins
and gangliosides on their surface. The interaction of RC16 with
sialic acid may be attributed to the presence of the 4-membered
azetidine ring on its hydrophilic head that links the polysialic acid
residues of the tumor cell membranes (27–29). Indeed azetidines
are known to easily react with nucleophiles undergoing acid
catalyzed ring opening reactions (30–32) due to their high ring
strain energy, especially in the presence of substitution like in
RC16 where the substituent is represented by a cyclic structure.
The RC16 interaction with polysialic acid is expected to produce
structural modifications on the glycoproteins and gangliosides of
the tumor cell surface thus inducing perturbations to the func-
tional properties of the cell membrane that, in addition to the
other alterations induced in mitochondria and lysosomes, con-
tribute to the final antitumor activity of RC16. In normal cells, on
the contrary, the very limited expression of sialic acid avoids any
significant interaction of RC16 with the cell surface.
The molecular mechanisms underlying the observed intra-
cellular effects are not completely clear, but the particular
Fig. 4 Electron microscopic analysis of RC16 treated neuroblastoma cells. (a) TEM image of SH-SY5Y cells treated with RC16 at 24 h showing damaged
mitochondria, multilamellar bodies and lysosomes (bar: 100 nm). (b) TEM image of human fibroblasts treated with RC16 5 M at 24 h showing a preserved
morphology with intact mitochondria and vesicles correlated with autophagy (bar: 100 nm). (c, d) Electron microscopy images of RC16 micelles formed by the
spontaneous self-assembling of the amphiphilic RC16 in the presence of SH-SY5Y cells with 20 μM RC16. SEM image(C, bar: 1 μm), TEM image (D, bar:
200 nm). Arrows indicate the presence of micelles on the cell surface.
Table III Cell killing activity of Doxorubicin, Paclitaxel and Etoposide
Complexed with R-C16*
Complex % CTR Free drug % CTR
RC16-DOXO 11.63± 1.29 DOXO 27.62± 0.55
RC16-PTX 40.34± 3.51 PTX 56.93± 4.61
RC16-ETO 35.26± 2.08 ETO 65.80± 5.76
*CHLA-20 cells were seeded in 96 well plates (2× 104 cells /plate) and after
24 h they were treated with the complexes (3 μM) or with the free drugs at
concentrations corresponding to those present in the complexes. After 48 h,
the effect on cell number was evaluated by MTT assay. Cell viability was
expressed as a percent of the untreated CHLA-20 cells (CTR). Data are
representative of three independent experiments (p<0.05)
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molecular structure of RC16 may account for its multiple
mechanisms of action. Indeed RC16, as the other RCn, is
comprised of 4, 6 and 7 membered rings condensed in a
unique tricyclic assembly linked to an alkyl linear tail. The
hydrophobic cycles surrounding the amine groups in the tri-
cyclic assembly provide a counter-balance to the hydrophilic-
ity increase triggered by the amine groups’ protonation in an
aqueous physiological environment thus allowing the mole-
cules to partition through biological membranes in spite of
the presence of positive charges. Thus the observed damage
to the inner mitochondrial membranes and the increase in the
cell ROS levels in the tumor cells may be attributed to an
accumulation of RC16 in mitochondria. This accumulation
might be promoted by both the negative transmembrane po-
tential of the mitochondrial inner membrane (negative inside),
which favors passage of protonated molecules into the matrix,
and by the acidic pH of the intermembrane space which at-
tracts amine molecules from the cytoplasm inside the mito-
chondria (14). Moreover, the high content of negatively
charged phospholipids such as cardiolipin on the outer mito-
chondrial membrane might further favor accumulation of
protonated molecules on the mitochondrial surface (33).
Similarly, the observed alterations of the lysosomes in the
tumor cells treated with RC16 may be attributed to an
accumulation of RC16 in the acidic inner environment of
lysosomes driven by the same suitable hydrophilic/
hydrophobic balance of the molecule allowing its partition
across the lysosomal membrane and a further protonation
inside (10–13).
In addition to differential expression of sialic acid, we hy-
pothesize that the differential effects of RC16 on tumor com-
pared with normal cells are due to differences in organelle
membrane potentials. We observed the mitochondria and ly-
sosomes alterations and the ROS increase after treatment
with RC16 in cancer cells but not in normal cells. This finding
is in accordance with the observation that the mitochondria of
cancer cells, in contrast to normal cells, are characterized by a
very large membrane potential across the mitochondrial
membrane (up to 150–160 mV, negative inside) driving an
extensive uptake of partitionable amines within the mitochon-
drial matrix (14–16). Likewise, the lysosomes of cancer cells
are characterized by an increase in lysosomal enzymes and a
deregulation of the enzymatic functions which, providing
acidification defects and metabolic perturbations, may make
Fig. 5 Evaluation of intracellular ROS and the interaction of RC16 with sialic acid. (a) Measurement of intracellular ROS in A673, 143.98.2 and SH-SY5Y after
treatment with 5 μM RC16 for 15 h or 24 h. (p<0.05). (b) Anticancer effect of RC16 (3 μM) on S462.TY cells (RC16) in comparison with the same cells
previously treated with Neuraminidase (50mU/ml) (RC16-NE). (c) Tumor cells treated with RC16 (3 μM) or a mixture of RC16 + Sialic Acid (3 μM:3 μM) or pure
Sialic Acid (3 μM) for 24 h.
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the lysosomal structure more sensitive to the accumulation of
partitionable amines (17,18). The mechanism of cell death
induced by RC16 appears to be mostly via apoptosis, involving
the activation of initiator caspases (caspase-2, caspase-8, cas-
pase-9, caspase-10), executioner caspases (caspase-3, caspase-
6) and also pro-inflammatory caspases (caspase-1 and caspase-
13). The role of the pro-inflammatory caspases in cell death is
likely related to their ability to induce host inflammatory re-
sponses in vivo, thus their contribution to cell death may be
observed in vivo but not in vitro. While the ability to accumulate
into the mitochondria and the lysosomes of tumor cells is
present in other amine-type antitumor drugs such as the
Delocalized Lipophilic Cations (Rodhamine, MKT-077 F16
and Dequalinium) and the Lysosomotropic Drugs
(Chloroquine and MDL 72527) (32,34–37), the ability to in-
teract with sialic acid is unique to RC16.
The generalized nature of the effects of RC16 may have a
distinct advantage over drugs that attack specific molecular
targets as it may be more difficult for cells to develop resis-
tance. Cells are able to develop resistance to drugs that bind
DNA, RNA or RTKs through the expression of P-glycopro-
tein, Multidrug-Resistance associated Proteins, activation of
alternative RTK pathways, or acquisition of non-binding mu-
tations (7). Down-regulation of sialic acids may be a mecha-
nism whereby cells could escape the effects of RC16, though
such global dysregulation may not be compatible with the
tumorigenic phenotype.
It will likely be possible to further increase the therapeutic
efficacy of RC16. For example, we did not optimize drug ex-
posure by maintaining constant drug plasma concentrations
over time as the well known limitations imposed by the mouse
models make it difficult to test a continuous infusion regimen.
Without continuous infusion, it is possible to reach plasma
drug concentrations in the therapeutic window for limited
periods of time followed by decrease in concentration which
may allow the tumor mass to resume its growth. RC16 distrib-
utes to the gastrointestinal tract, liver and kidney due to its
amine character which, following protonation, drives the
RC16 circulating molecules into the distribution pathway of
the cationic compounds. In this pathway amajor role is played
by the organic cation transporters (OCT1 and OCT2) which
are highly expressed in basolateral membranes of hepatocytes,
intestine enterocytes and renal proximal tubular cells and me-
diate the elimination of a variety of cationic compounds such
Fig. 6 Pharmacokinetic and biodistribution studies of RC16 in mice. Plasma concentration-time profiles of RC16 after intravenous or oral (a) administration at
1 mg/kg or 2 mg/kg respectively (n=1 mouse per time point). (b) Non-compartmental pharmacokinetic parameters of RC16. t1/2α and t1/2β represent half-lives
in the initial distribution phase and in the subsequent elimination phase respectively; C0 is the initial drug concentration in blood; Vd is the volume of distribution;
AUC is the area under the blood concentration versus time curve. (c) Biodistribution of RC16 labelled with Cell-Vue Maroon (dye:RC16 1:100 mol:mole) in nude
mice bearing CHLA-20 tumors (n=3). The labelled RC16 was injected i.v. at 1 mg/kg and whole-body images of the mice were taken at 12, 24 and 36 h after i.v
injection. (d) Fluorescence intensity in tissues and organs at 12, 24 and 48 h after the i.v. injection of RC16 labelled with Cell-Vue Maroon.
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as drugs, toxins, and endogenous molecules (38), but whether
they play a role in RC16 metabolism is unknown. Although a
limitation of the study is that we only tested one mouse per
timepoint, the pilot pharmacokinetic data demonstrated we
were able to achieve concentrations in the 150 to 200 ng/mL
range (approximately 500–600 nM) at the low i.v. dose of
1 mg/kg. Oral dosing with RC16 may be worth further study,
as we did estimate an oral bioavailability of approximately 6%
based on the pilot pharmacokinetic data. We have not deter-
mined an MTD for this route of administration, and higher
doses that could produce similar or even greater plasma ex-
posures may be achievable via oral gavage.
In addition to its activity as an antitumor drug, RC16 has
been evaluated for its ability to complex other bioactive mol-
ecules such as Doxorubicin, Etoposide and Paclitaxel. The
complexation ability of RC16 is based on its amphiphilic
character triggering a spontaneous self-assembling of mole-
cules in water with formation of micelles. As it is well known
that micelles with a hydrophobic inner core and a hydrophilic
outer shell may encapsulate hydrophobic or partially hydro-
phobic drugs (39,40), forming micellar aggregates also re-
ferred to as complexes, complexation of poorly water soluble
drugs into the micelles may improve their aqueous solubility
and consequently their bioavailability and therapeutic efficacy
(41–46). Micellar complexation may moreover modify the
drug disposition in the body by preventing uncontrolled drug
distribution and favoring drug accumulation in solid tumors
where the discontinuity of the capillaries and the lack of an
efficient lymphatic drainage supports the entrapment and re-
tention of nanoparticulate systems such as micelles, liposomes
or soluble macromolecules (39,40,47). The micellar com-
plexation of Paclitaxel and Etoposide is regarded with
Fig. 7 Evaluation of RC16 for in vivo efficacy. (a) Inhibition of the tumor growth in tumor xenograft models by intravenous administration (CHLA-20, SK-N-AS,
A673, A549, S462TY) or oral administration (CHLA-20) of RC16 . RC16 was given through the tail vein at the dose of 1 mg/kg, 3 times a week for 3 weeks or
gavaged at the dose of 2 mg/kg/day for 3 weeks. RTV is obtained by TVn/TV0, where TVn is the tumor volume at day n and TV0 is the tumor volume at day 0) (P-
values < 0.05). (b) Improvement of the survival in a metastatic model of murine neuroblastoma (Neuro-2A) by intravenous administration of RC16. RC16 was
injected through the tail vein at doses of 20 μg (n=6) or 40 μg/mouse (n=6) (plotted together) (p-values < 0.05).
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great interest to improve their bioavailability (48,49) over-
coming the adverse reactions associated with the currently
marketed formulations. Indeed, apart from Abraxane®,
consisting in nanoparticles of Paclitaxel and human serum
albumin, all the other marketed formulations of Paclitaxel
and Etoposide contain excipients such as Cremophor-EL,
ethanol, benzyl alcohol, polysorbate-80 which have been
associated with serious side effects (50). The micellar com-
plexation of Doxorubicin is also considered a very interest-
ing approach but in this case the main purpose is a modi-
fication of the drug biodistribution in addition to an in-
crease in its solubility. Indeed Doxorubicin induces a
strong dose-limiting cardiotoxicity (51), and its encapsula-
tion in micelles or liposomes has proven to decrease its
distribution to the heart with a reduction of its cardiotoxic
effect (52). Simultaneously, increased solubility by micellar
complexation has proven to enhance its therapeutic activity
(53).
In summary, we have developed a novel, multimechanistic
antitumor drug class that shows promise for cancer the-
rapy. These amphiphilic amines bind to and induce anti-
cancer activity by several mechanisms of action with dif-
ferential effects on normal cells, resulting in a clinically
significant therapeutic window. Furthermore, these agents
are useful for encapsulating traditional chemotherapies
and thereby enhancing their efficacy and reducing their
side-effects.
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